- Home
- LCFY vs HOTH Comparison
LCFY vs HOTH Comparison
Compare LCFY & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- HOTH
- Stock Information
- Founded
- LCFY 2009
- HOTH 2017
- Country
- LCFY Australia
- HOTH United States
- Employees
- LCFY N/A
- HOTH N/A
- Industry
- LCFY
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- LCFY
- HOTH Health Care
- Exchange
- LCFY Nasdaq
- HOTH Nasdaq
- Market Cap
- LCFY 7.3M
- HOTH 7.6M
- IPO Year
- LCFY 2022
- HOTH 2019
- Fundamental
- Price
- LCFY $6.30
- HOTH $0.82
- Analyst Decision
- LCFY
- HOTH Strong Buy
- Analyst Count
- LCFY 0
- HOTH 4
- Target Price
- LCFY N/A
- HOTH $4.75
- AVG Volume (30 Days)
- LCFY 19.2K
- HOTH 1.0M
- Earning Date
- LCFY 11-12-2024
- HOTH 11-12-2024
- Dividend Yield
- LCFY N/A
- HOTH N/A
- EPS Growth
- LCFY N/A
- HOTH N/A
- EPS
- LCFY N/A
- HOTH N/A
- Revenue
- LCFY $3,169,582.00
- HOTH N/A
- Revenue This Year
- LCFY N/A
- HOTH N/A
- Revenue Next Year
- LCFY N/A
- HOTH N/A
- P/E Ratio
- LCFY N/A
- HOTH N/A
- Revenue Growth
- LCFY N/A
- HOTH N/A
- 52 Week Low
- LCFY $2.20
- HOTH $0.58
- 52 Week High
- LCFY $11.23
- HOTH $1.73
- Technical
- Relative Strength Index (RSI)
- LCFY 63.67
- HOTH 45.88
- Support Level
- LCFY $5.54
- HOTH $0.83
- Resistance Level
- LCFY $7.99
- HOTH $0.90
- Average True Range (ATR)
- LCFY 0.39
- HOTH 0.08
- MACD
- LCFY 0.17
- HOTH -0.00
- Stochastic Oscillator
- LCFY 61.62
- HOTH 3.10
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.